

**INDO-BANGLA PHARMACEUTICALS LTD**  
**STATEMENT OF FINANCIAL POSITION (Un-Audited)**  
As at 31 December 2022

Particulars	Notes	Amounts in Taka	
		31st Dec 2022	30th June 2022
<b>ASSETS:</b>			
<b>Non-current Assets:</b>		<b>1,359,522,481</b>	<b>1,354,903,129</b>
Property, Plant and Equipment	3.00	1,328,779,992	1,331,343,626
Capital Work In Progress	4.00	30,742,489	23,559,503
<b>Current Assets:</b>		<b>565,559,679</b>	<b>538,891,584</b>
Inventories	5.00	212,747,862	181,085,873
Trade & Other Receivables	6.00	215,720,419	213,933,121
Advance, Deposits and Prepayments	7.00	112,968,607	110,181,071
Cash and Cash equivalents	8.00	24,122,791	33,691,519
<b>TOTAL ASSETS</b>		<b>1,925,082,160</b>	<b>1,893,794,713</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholders' Equity:</b>		<b>1,624,278,687</b>	<b>1,625,035,557</b>
Share Capital	9.00	1,162,051,780	1,162,051,780
Retained Earnings	10.00	462,226,907	462,983,777
<b>NON-CURRENT LIABILITIES</b>		<b>121,757,315</b>	<b>114,560,897</b>
Deferred Tax Liability	11.00	121,757,315	114,560,897
<b>Current Liabilities:</b>		<b>179,046,158</b>	<b>154,198,259</b>
Short Term Loan	12.00	87,620,000	75,357,000
Unclaimed Dividend	13.00	12,333,390	13,880,231
Provision for WPPF	14.00	2,566,817	1,586,028
Trade Payables	15.00	615,989	926,961
Provision for Taxes	16.00	52,433,047	50,877,345
Liabilities for Expenses	17.00	23,476,916	11,570,694
<b>TOTAL OWNER'S EQUITY AND LIABILITY</b>		<b>1,925,082,160</b>	<b>1,893,794,713</b>
Net Asset Value (NAV) Per Share	26.00	13.98	13.98

Annexed notes form an integral part of these financial statements.






  
Chief Financial Officer    Company Secretary    Director    Managing Director    Chairman






Signed in terms of our separate report of even date annexed.

Place: Dhaka

Date: January 30, 2023

**INDO-BANGLA PHARMACEUTICALS LTD**  
**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)**  
For the Second quarter ended 31 December 2022

Particulars	Notes	Amounts in Taka			
		1st July 2022 to 31st Dec 2022	1st July 2021 to 31st Dec 2021	1st Oct 2022 to 31st Dec 2022	1st Oct 2021 to 31st Dec 2021
Net Sales Revenue	18.00	221,942,118	290,871,259	100,452,298	132,120,797
Less: Cost of Sales	19.00	157,559,517	184,754,628	74,740,674	91,263,646
<b>Gross Profit</b>		<b>64,382,601</b>	<b>106,116,631</b>	<b>25,711,624</b>	<b>40,857,151</b>
Less: Operating Expenses:		44,906,294	27,689,098	31,896,850	13,826,930
Administrative Expenses	20.00	27,982,276	18,987,024	19,379,021	9,711,331
Financial Expenses	21.00	2,975,032	1,894,837	1,770,000	886,500
Selling & Distributing Expenses	22.00	13,948,986	6,807,237	10,747,828	3,229,099
<b>Profit from Operations</b>		<b>19,476,307</b>	<b>78,427,533</b>	<b>(6,185,225)</b>	<b>27,030,221</b>
Add: Non Operating Income:	23.00	1,120,250	429,080	700,000	182,450
<b>Profit before Contribution to WPPF &amp; Welfare Fund</b>		<b>20,596,557</b>	<b>78,856,613</b>	<b>(5,485,225)</b>	<b>27,212,671</b>
Less: Contribution to WPPF & Welfare Fund	14.00	980,788	3,755,077	(261,201)	1,295,841
<b>Profit before Tax</b>		<b>19,615,768</b>	<b>75,101,536</b>	<b>(5,224,024)</b>	<b>25,916,830</b>
Less: Income Tax Expenses:		8,752,120	16,897,845	4,521,298	5,831,286
Current Tax	24.00	1,555,703	6,491,768	742,714	631,814
Deferred Tax	11.00	7,196,418	10,406,077	3,778,584	5,199,472
<b>Net Profit for the period</b>		<b>10,863,648</b>	<b>58,203,691</b>	<b>(9,745,322)</b>	<b>20,085,544</b>
Basic Earnings per share (EPS)	25.00	0.09	0.50	(0.08)	0.17

 Chief Financial Officer  
 Company Secretary  
 Director  
 Managing Director  
 Chairman

Dated: Dhaka  
Date: January 30, 2023

**INDO-BANGLA PHARMACEUTICALS LTD**  
**STATEMENT OF CHANGES IN EQUITY (Un-Audited)**  
**For the Second quarter ended 31 December, 2022**

Particulars	Share Capital	Retained Earnings	Total Equity
	Note - 09	Note : 10	
Balance as at 01-07-2022	1,162,051,780	462,983,777	1,625,035,557
Cash Dividend	-	(11,620,518)	(11,620,518)
Net Profit for the period	-	10,863,648	10,863,648
Balance as at 30-09-2022	1,162,051,780	462,226,907	1,624,278,687

**STATEMENT OF CHANGES IN EQUITY**  
**For the Second quarter ended 31 December, 2021**

Particulars	Share Capital	Retained Earnings	Total Equity
	Note - 09	Note : 10	
Balance as at 01-07-2021	1,137,371,400	488,046,975	1,625,418,375
Cash Dividend	-	(25,556,851)	(25,556,851)
Net Profit for the period	-	58,203,691	58,203,691
Balance as at 30-09-2021	1,137,371,400	520,693,815	1,658,065,215



Chief Financial Officer  
Place: Dhaka




Company Secretary



Director



Managing Director




Chairman

Date: January 30, 2023


**INDO-BANGLA PHARMACEUTICALS LIMITED**  
**Statement Of Cash Flows (Un-Audited)**  
**For the Period ended 31st December, 2022**


Particulars	Amounts in Taka	
	31st December 2022	31st December 2021
<b>Cash Flow from Operating Activities</b>		
Cash receipts from customers	220,154,820	255,265,450
Cash receipts from others income	420,250	429,080
Cash payment to Suppliers	(156,076,331)	(157,755,806)
Cash payment to Employees	(21,508,189)	(25,611,575)
Cash payment to Others	(32,933,581)	(17,381,510)
<b>Cash Generate from operation</b>	10,056,969	54,945,639
Cash payment against income Tax	(4,325,640)	(8,044,763)
<b>Net Cash from Operating Activities</b>	<b>5,731,329</b>	<b>46,900,876</b>
<b>Cash Flow from Investing Activities</b>		
Acquisition of property, plant and equipment	(1,000,000)	(13,642,530)
Receive from Sale of Land	2,700,000	-
Paid for Work In Progress	(25,682,986)	(141,650)
<b>Net Cash used in Investing Activities</b>	<b>(23,982,986)</b>	<b>(13,784,180)</b>
<b>Cash Flow from Financing Activities</b>		
Short Term Loan	12,263,000	(4,143,281)
Financial Expenses	(2,033,229)	(2,621,080)
Paid for Dividend Refund	(1,546,841)	-
<b>Net Cash from Financing Activities</b>	<b>8,682,930</b>	<b>(6,764,361)</b>
<b>Net increase in Cash and Cash equivalents</b>	<b>(9,568,728)</b>	<b>26,352,335</b>
Cash and Cash Equivalents at beginning of the period	33,691,519	22,479,787
<b>Cash and Cash Equivalent at end of the Period</b>	<b>24,122,791</b>	<b>48,832,122</b>
<b>Net Operating Cash Flows Per Share (NOCFPS)</b>	<b>0.05</b>	<b>0.40</b>

  
Chief Financial Officer

  
Company Secretary

  
Director

  
Managing Director

  
Chairman

Dated: Dhaka  
Date: January 30, 2023